Bioxytran (BIXT) Other Operating Expenses (2012 - 2026)
Bioxytran (BIXT) posted Other Operating Expenses of $1.5 million for Q1 2026, up 304.24% sequentially from $369486.0 in Q4 2025, and up 6728.82% YoY from $21872.0 in Q1 2025.
Bioxytran (BIXT) Other Operating Expenses (2012 - 2026) Analysis & Trends
Bioxytran has reported Other Operating Expenses for 11 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Other Operating Expenses rose 6728.82% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 301.18% YoY) and the FY2025 annual result came in at $740280.0, down 21.52% from the prior year.
- Other Operating Expenses advanced to $1.5 million in Q1 2026 per BIXT's latest filing, from $369486.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $1.5 million in Q1 2026 and troughed at -$47719.0 in Q4 2023.
- A 5-year average of $251027.7 and a median of $161447.0 in 2024 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Operating Expenses surged 8609.36% in 2022, then sank 126.3% in 2023.
- Over 5 years, Other Operating Expenses stood at $181464.0 in 2022, then plunged by 126.3% to -$47719.0 in 2023, then soared by 589.15% to $233416.0 in 2024, then soared by 58.3% to $369486.0 in 2025, then jumped by 304.24% to $1.5 million in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $1.5 million, $369486.0, and $336874.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Bioxytran | 2.47 Mn | 2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 369,486.00 |
| Sep 30, 2025 | 336,874.00 |
| Jun 30, 2025 | 22,048.00 |
| Mar 31, 2025 | 21,872.00 |
| Dec 31, 2024 | 233,416.00 |
| Sep 30, 2024 | 137,133.00 |
| Jun 30, 2024 | 161,447.00 |
| Mar 31, 2024 | 431,232.00 |
| Dec 31, 2023 | -47,719.00 |
| Sep 30, 2023 | 436,558.00 |
| Jun 30, 2023 | 303,110.00 |
| Mar 31, 2023 | 23,600.00 |
| Dec 31, 2022 | 181,464.00 |
| Sep 30, 2022 | 73,507.00 |
| Jun 30, 2022 | 46,723.00 |
| Mar 31, 2022 | 43,120.00 |
| Dec 31, 2021 | -238,465.00 |
| Sep 30, 2021 | 844.00 |
| Jun 30, 2021 | 51,050.00 |